Board of Directors













C. Geoffrey Davis, Ph.D.
President and CEO

Dr. Davis was a founder and the Chief Scientific Officer for Abgenix, Inc. in Fremont, California, where he led the development of the XenoMouse® technology, was involved in the research and development of Vectabix®, a fully human monoclonal antibody approved for colorectal cancer, and guided the discovery of 11 other antibodies currently in clinical trials.  Abgenix was acquired by Amgen in early 2006. Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc.  Dr. Davis received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at the University of Texas Southwestern Medical School at Dallas.  He is the author of 37 publications and is an inventor on 11 issued patents.


--------------------------------------------------------------------------------

John Klacking, Ph.D.

Dr. Klacking is a very experienced financial executive.  He was most recently a Senior Vice President at the investment firm Smith Barney.  He serves on the Boards of three universities, five corporations, and three non-profits / foundations.  Dr. Klacking also cofounded in 1990 the predecessor to Southwest Analytical Laboratory located in Las Vegas.  He has authored / co-authored over 300 financial articles.  He obtained his Ph.D. in Biochemistry from the University of Nevada.


--------------------------------------------------------------------------------

Gregory T. Went, Ph.D.

Dr. Went is a successful biotechnology entrepreneur.  He is currently the Chairman and CEO of Adamas Pharmaceuticals, Inc.  In 1992, Dr. Went co-founded CuraGen Corporation, dedicated to applying genomics to the discovery of new drug targets, with Jonathan M. Rothberg.  Subsequent to Curagen, Dr. Went served as Director and Chief Operating Officer of DNA Sciences.  Dr. Went received his Ph.D. from the University of California, Berkeley.  He also serves as an advisor/board member to 10 companies and venture firms.  He has published in the fields of spectroscopy and genomics and is an inventor on over 45 issued and pending patents.